BGB C354
Alternative Names: BG-C354; BGB-C354Latest Information Update: 17 Mar 2026
At a glance
- Originator BeiGene
- Developer BeOne Medicines
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 17 Mar 2026 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Australia, China (IV)
- 17 Mar 2026 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA, Australia, China (IV)
- 25 Apr 2025 Pharmacodynamics data from a pre-clinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)